Abstract
During the last decades, various strategies have been optimized to enhance clearance of a variable spectrum of retained molecules to ensure hemodynamic tolerance to fluid removal and improve long-term survival in patients affected by end-stage kidney disease. Treatment effects are the result of the interaction of individual patient characteristics with device characteristics and treatment prescription. Historically, the nephrology community aimed to provide adequate treatment, along with the best possible quality of life and outcomes. In this article, we analyzed blood purification techniques that have been developed with their different characteristics.
Journal Section:
Hemodialysis - Guidelines
References
1.
Meyer TW, Hostetter TH. Uremia. N Engl J Med. 2007;357(13):1316–25.
2.
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238–52.
3.
Himmelfarb J, Ikizler TAN Engl J Med Overseas Ed. 2010 Nov 4;363(19):1833–45.
4.
Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int. 2006 Apr;69(7):1222–8.
5.
Kimata N, Tsuchiya K, Akiba T, Nitta K. Differences in the characteristics of dialysis patients in Japan compared with those in other countries. Blood Purif. 2015;40(4):275–9.
6.
Kurella M, Chertow GM. Dialysis session length (“t”) as a determinant of the adequacy of dialysis. Semin Nephrol. 2005;25(2):90–5.
7.
Lacson E, Lazarus M. Dialysis time: does it matter? A reappraisal of existing literature. Curr Opin Nephrol Hypertens. 2011;20(2):189–94.
8.
Lowrie EG, Laird NM, Parker TF, sargent J. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med. 1981;305(20):1176–81.
9.
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347(25):2010–9.
10.
Gotch FA, Levin NW. Daily dialysis: the long and the short of it. Blood Purif. 2003;21(4–5):271–81.
11.
FHN Trial Group; Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287–300.
12.
Yan Y, Wang M, Zee J, Schaubel D, Tu C, Qian J, et al. Twice-weekly hemodialysis and clinical outcomes in the China dialysis outcomes and practice patterns study. Kidney Int Rep. 2018 Jul;3(4):889–96.
13.
Deira J, Suárez MA, López F, García-Cabrera E, Gascón A, Torregrosa E, et al. IHDIP: a controlled randomized trial to assess the security and effectiveness of the incremental hemodialysis in incident patients. BMC Nephrol. 2019 Jan 9;20(1):8.
14.
Caton E, Sharma S, Vilar E, Farrington K. Impact of incremental initiation of haemodialysis on mortality: a systematic review and meta-analysis. Nephrol Dial Transpl. 2023 Feb 13;38(2):435–46.
15.
Ibrahim A, Chan CT. Managing kidney failure with home hemodialysis. Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1268–73.
16.
Sgarabotto L, Kazory A, Brendolan A, Di Lullo L, Zanella M, Ronco C. The science of extracorporeal ultrafiltration: introducing a novel miniaturized device. Cardiorenal Med. 2023 Feb 14:46–55.
17.
Lunderquist A. On the artificial kidney XXI.: the efficacy of the dialyser-ultrafilter intended for human use.: including a preliminary report on treatment of oedemic patients by means of ultrafil. Acta Med Scand. 2009;143(4):307–14.
18.
Schmidt R, Herrera R, Holtz M, Falkenhagen D, Osten B, Klinkmann H. [Technic and indication for controlled ultrafiltration]. Z Gesamte Inn Med. 1980 Aug 15;35(16):suppl 55–8.
19.
Henderson LW. Current status of hemofiltration. Artif Organs. 1978 May;2(2):120–4.
20.
Andreucci VE, Calderaro V, Memoli B, Terracciano V. A new semiautomated apparatus for hemofiltration. J Dial. 1979;3(2–3):165–71.
21.
Miller JH, Shinaberger JH, Kraut JA, Gardner PW. A volume controlled apparatus for ultrafiltration and hemofiltration with acetate or bicarbonate solutions. Trans Am Soc Artif Intern Organs. 1979;25:404–8.
22.
Kishimoto T, Yamagami S, Tanaka H, Ohyama T, Yamamoto T, Yamakawa M, et al. Superiority of hemofiltration to hemodialysis for treatment of chronic renal failure: comparative studies between hemofiltration and hemodialysis on dialysis disequilibrium syndrome. Artif Organs. 1980 May;4(2):86–93.
23.
Klein E. Middle molecule definition in terms of membrane permeability. Artif Organs. 1981;4(Suppl l):46–50.
24.
Shaldon S. Role of small molecule removal in the control of treatment morbidity with haemodialysis and haemofiltration. Proc Eur Dial Transpl Assoc. 1981;18:249–55.
25.
De Fremont JF, Coevoet B, Dkhissi H, Pruna A, Moriniere P, Galy C, et al. Is blood urea nitrogen as good a guide for hemofiltration as for hemodialysis?N Engl J Med. 1982 Oct 14;307(16):1025–6.
26.
Quellhorst E, Schuenemann B, Hildebrand U, Falda Z. Response of the vascular system to different modifications of haemofiltration and haemodialysis. Proc Eur Dial Transpl Assoc. 1980;17:197–204.
27.
Kolff WJ. [The artificial kidney and the experiences gained with it in the clinic]. Ned Tijdschr Geneeskd. 1946;90(7–8):155–8.
28.
Kolff WJ, Berk HT, ter Welle M, van der Ley AJ, van Dijk EC, van Noordwijk J. The artificial kidney: a dialyser with a great area. 1944. J Am Soc Nephrol. 1997 Dec;8(12):1959–65.
29.
Kolff WJ. Lasker Clinical Medical Research Award. The artificial kidney and its effect on the development of other artificial organs. Nat Med. 2002;8(10):1063–5.
30.
Meyer TW, Leeper EC, Bartlett DW, Depner TA, Lit YZ, Robertson CR, et al. Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J Am Soc Nephrol. 2004;15(7):1927–35.
31.
Luo FJ, Patel KP, Marquez IO, Plummer NS, Hostetter TH, Meyer TW. Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: a pilot crossover trial. Am J Kidney Dis. 2009;53(6):1042–9.
32.
Bowry SK, Kircelli F, Misra M. Flummoxed by flux: the indeterminate principles of haemodialysis. Clin Kidney J. 2021 Dec;14(Suppl 4):i32–i44.
33.
Ronco C, Clark WR. Haemodialysis membranes. Nat Rev Nephrol. 2018 Jun;14(6):394–410.
34.
Mohajerani F, Clark WR, Ronco C, Narsimhan V. Mass transport in high-flux hemodialysis: application of engineering principles to clinical prescription. Clin J Am Soc Nephrol. 2022 May;17(5):749–56.
35.
Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009;20(3):645–54.
36.
Rangel AV, Kim JC, Kaushik M, Garzotto F, Neri M, Cruz DN, et al. Backfiltration: past, present and future. Contrib Nephrol. 2011;175:35–45.
37.
Lorenzin A, Golino G, de Cal M, Pajarin G, Savastano S, Lupi A, et al. Flow dynamic analysis by contrast-enhanced imaging techniques of medium cutoff membrane hemodialyzer. Blood Purif. 2022;51(2):138–46.
38.
Maduell F, Broseta JJ. Hemodiafiltration (HDF) versus expanded hemodialysis (HDx). Semin Dial. 2022 Sep;35(5):436–9.
39.
Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transpl. 2017;32(1):165–72.
40.
Kirsch AH, Rosenkranz AR, Lyko R, Krieter DH. Effects of hemodialysis therapy using dialyzers with medium cut-off membranes on middle molecules. Contrib Nephrol. 2017;191:158–67.
41.
Cho NJ, Jeong SH, Lee KY, Yu JY, Park S, Lee EY, et al. Clinical safety of expanded hemodialysis compared with hemodialysis using high-flux dialyzer during a three-year cohort. J Clin Med. 2022 Apr 18;11(8):2261.
42.
Lim JH, Jeon Y, Yook JM, Choi SY, Jung HY, Choi JY, et al. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial. Sci Rep. 2020 Sep 29;10(1):16062.
43.
Ariza JG, Walton SM, Suarez AM, Sanabria M, Vesga JI. An initial evaluation of expanded hemodialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia. Ther Apher Dial. 2021 Oct;25(5):621–7.
44.
Lorenz G, Shen Y, Hausinger RI, Scheid C, Eckermann M, Hornung S, et al. A randomized prospective cross over study on the effects of medium cut-off membranes on T cellular and serologic immune phenotypes in hemodialysis. Sci Rep. 2022 Sep 30;12(1):16419.
45.
Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013 Feb;24(3):487–97.
46.
Nubé MJ, Peters SAE, Blankestijn PJ, Canaud B, Davenport A, Grooteman MPC, et al. Mortality reduction by post-dilution online-haemodiafiltration: a cause-specific analysis. Nephrol Dial Transpl. 2017 Mar 1;32(3):548–55.
47.
Maduell F, Arias M, Fontseré N, Vera M, Masso E, Garro J, et al. What infusion flow should be used for mid-dilution hemodiafiltration?Blood Purif. 2010;30(1):25–33.
48.
Pedrini LA, Wiesen G. Overcoming the limitations of post-dilution on-line hemodiafiltration: mixed dilution hemodiafiltration. Contrib Nephrol. 2011;175:129–40.
49.
Canaud B, Lertdumrongluk P. Ultrapure dialysis fluid: a new standard for contemporary hemodialysis. Nephrourol Mon. 2012 Summer;4(3):519–23.
50.
Pérez-García R, García Maset R, Gonzalez Parra E, Solozábal Campos C, Ramírez Chamond R, Martín-Rabadán P, et al. Guideline for dialysate quality of Spanish Society of Nephrology (second edition, 2015). Nefrologia. 2016 May-Jun;36(3):e1–52.
51.
Leber HW, Wizemann V, Goubeaud G, Rawer P, Schütterle G. Hemodiafiltration: a new alternative to hemofiltration and conventional hemodialysis. Artif Organs. 1978 May;2(2):150–3.
52.
Canaud B, Flavier JL, Argilés A, Stec F, Nguyen QV, Bouloux C, et al. Hemodiafiltration with on-line production of substitution fluid: long-term safety and quantitative assessment of efficacy. Contrib Nephrol. 1994;108:12–22.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
